ANI Pharmaceuticals ANIP Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ANI Pharmaceuticals's accrued liabilities, current?
- ANI Pharmaceuticals (ANIP) reported accrued liabilities, current of $13.74M in Q1 2026.
- How has ANI Pharmaceuticals's accrued liabilities, current changed year-over-year?
- ANI Pharmaceuticals's accrued liabilities, current increased by 14.2% year-over-year, from $12.03M to $13.74M.
- What is the long-term trend for ANI Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued liabilities, current has grown at a 47.2% compound annual growth rate (CAGR), from $2.46M to $16.97M.